CI

At a glance

ClinicalIndex Comparison Record
N/ANot Yet Recruiting· 6 target
Drug / intervention
RK-4 ICO injection +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07514949
NCT07514949N/ANot Yet Recruiting

The Feasibility and Safety of RK-4 Injection Bypassing Blood-brain Barrier in the Treatment of Acute Large Hemispheric Infarction Using Intracalvariosseous Injection Device

yilong Wang·interventional·Posted Apr 7, 2026·Updated Apr 7, 2026

In Brief

A clinical study evaluating RK-4 ICO injection and Conventional treatment for Stroke and 2 related conditions. Not yet recruiting, targeting 6 participants across 1 site.

Detailed Summary

A pilot study confirmed the feasibility and safety of neuroprotectant RK-4 intracalvariosseous(ICO) injection in patients with malignant middle cerebral artery infarction (mMCAI), showing a trend in improving 90-day functional scores compared to conventional treatment. The aim of this trial is to investigate the feasibility and safety of neuroprotective agent RK-4 injection using intracalvariosseous injection device in patients with acute large hemispheric infarction (LHI) who has contraindications of reperfusion therapy or have got poor reperfusion therapy outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ANot Yet Recruiting
2027
First PostedApr 7, 2026
Enrollment StartApr 15, 2026
Primary CompletionNov 15, 2026
TodayJul 1, 2026
Enrollment to primary: 7 monthsPosted 3 months agoPrimary completion in 4 months

Interventions

RK-4 ICO injectiondevice

Patients included will be given skull outer plate drilling surgery and RK-4 ICO injection under local anesthesia and sedation using the intracalvariosseous injection device. The drilling and injection will be conducted once a day for 3 consecutive days.

Conventional treatmentother

standard treatment and management according to related guidelines